Just before the 23andMe SPAC deal closed, the stock belonging to its merger ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets ...

In 2007, 23andMe, named after the 23 pairs of chromosomes found in a human cell, was one of the first direct-to-consumer ...

Me on Sunday filed for bankruptcy in the U.S. after struggling with weak demand for its ancestry testing kits and a 2023 data ...

23andme says it owns the aggregated genetic data of its customers, meaning it can sell it to the highest bidder ...

The direct-to-consumer DNA testing service 23andMe filed for bankruptcy earlier this month, putting millions of customers' ...

GlaxoSmithKline also made a $300 million equity investment in 23andMe. When 23andMe went public ... if it shows that they have or are at high risk of developing a genetic disease or disorder.

Genetic analysis company 23andMe (ME) announced this week it's declaring bankruptcy and pursuing a sale, leading many customers to pursue deleting their data from the company. 23andMe was founded ...

23andMe is going bankrupt — underscoring the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations. When companies opt ...

23andMe bankruptcy underscores the risk of investing in most SPACs. - MarketWatch photo illustration/iStockphoto 23andMe is going bankrupt — underscoring the great ...

Just before the 23andMe SPAC deal closed ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets and have to redeem the ...